Content of the report:
- THE SHARE PRICE IS CLOSE TO ITS 12M TARGET LEVEL;
- SALES FOR 9M 2009 GREW 40% Y-O-Y;
- SOME DROP IN LIFE-STYLE GOODS IS POSSIBLE;
- GROWTH POSSIBILITIES ARE VERY WEAK;
- BUSINESS RISK FOR 2010 IS MEDIUM;
- QUARTERLY INCOME STATEMENT (historical);
- KEY FINANCIAL RATIOS (Historical)
Summary of the report:
Author of this report belives that the growth possibilities of Pharmstandard are very weak. Author does not expect the prices on drugs to experience significant growth in Russia.
To read this report and for more information visit:
http://www.balticbusinessanalysis.com/
This report provides analyst comment on company’s latest events and performance. Report contains target price, forecast on business risk (short-, mid-, and long-term) and growth possibilities (long-term) of the company, providing reader with necessary information to make decisions.
Key reasons to read this report:
- Report contains only relevant information, leaving out excessive data.
- Understand company’s opportunities, competitive situation and business risk.
- Understand which events influence company performance.
- Independent analyst comment and opinion.
